VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce a second provisional patent for a proprietary two-part processing method that involves…

Source

Previous articleRed Light Holland to Collaborate with Advocacy Group, Psychedelic Medicine Alliance Washington to Promote Proposed Psilocybin Legalization Bill in Washington State
Next articlePsygen Receives Dealer’s Licence from Health Canada